Randomized phase 2 trial of addition of dendritic cell vaccination to cyclophosphamide and TACE for hepatocellular carcinoma
Prof. David Adams
The randomized ImmunoTACE trial, at three centers in the UK, evaluated addition of dendritic cell (DC) vaccination to TACE plus preconditioning cyclophosphamide among patients with intermediate-stage hepatocellular carcinoma (HCC). The median progression-free survival was 18.6 months in the DC-cyclophosphamide-TACE group compared with 10.4 months in the cyclophosphamide-TACE group (HR 0.43; p=0.016). Addition of DC-infusions did not significantly increase the incidence or severity of adverse events. An enhance antigen (α-fetoprotein)-specific immune response was observed in patients receiving the DC vaccination. The authors conclude that addition of DC infusions to cyclophosphamide-TACE has shown promising preliminary activity,
